Literature DB >> 8263816

YM934, a novel K+ channel opener, activates ATP-sensitive K+ channels in cardiac myocytes.

M Yamada1, A Terzic, I Findlay, A Jahangir, W K Shen, Y Kurachi.   

Abstract

2-(3,4-Dihydro-2,2-dimethyl-6-nitro-2H-1,4-benzoxazin-4-yl)pyridin e N-oxide (YM934) is a newly synthesized benzoxazin. The effects of YM934 on ATP-sensitive K+ (KATP) channels in guinea pig cardiac ventricular myocytes and in an insulin-secreting cell line, HIT T15 beta-cells, were examined using the gigaohm-seal patch-clamp techniques. Under the whole-cell clamp condition, YM934 induced in ventricular myocytes a time-independent, glibenclamide-sensitive K+ current in a concentration-dependent fashion (EC50 = approximately 3 microM). On formation of inside-out patches in ATP-free solution, the KATP channel current abruptly appeared and then ran down. YM934 was applied to inside-out patches before, during and after channel "run-down." Because nucleoside diphosphates, such as uridine diphosphate (UDP), can induce channel openings after complete run-down, the effects of YM934 on the UDP-induced channel openings were also examined. Before run-down, YM934 enhanced KATP channel activity by decreasing the sensitivity of channels to intracellular ATP. YM934 also enhanced the partially run-down channel, even in the absence of ATP. After run-down, YM934 had no effect but could enhance the UDP-induced KATP channel openings. These effects of YM934 on cardiac KATP channels were similar to those of pinacidil and lemakalim. In HIT T15 beta-cells, 100 microM YM934 was ineffective in both cell-attached and inside-out patch configurations, suggesting the tissue-specific nature of the action of this novel K+ channel opener.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8263816

Source DB:  PubMed          Journal:  J Pharmacol Exp Ther        ISSN: 0022-3565            Impact factor:   4.030


  1 in total

1.  The role of extracellular Ca2+ in carbachol-induced tonic contraction of the pig detrusor smooth muscle.

Authors:  W Uchida; N Masuda; Y Shirai; K Shibasaki; N Satoh; T Takenada
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1994-10       Impact factor: 3.000

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.